About crovalimab
Complement C5 inhibitor monoclonal antibody
Used for
- Treats paroxysmal nocturnal hemoglobinuria (PNH) in adults and children aged 13 years or older weighing at least 40 kg.
Usual adult dose
For adults: 1,000 mg under the skin on day 1, then 340 mg on day 2; 680 mg on day 8, then 680 mg every 4 weeks.
Usual dose in children
For patients aged 13 years or older weighing at least 40 kg: dose is weight-based; the schedule includes a day 1 loading dose, day 2 dose, day 8 dose, then dosing every 4 weeks.
Common side effects
- Injection-site reactions
- Headache
- Infusion-related reactions
- Upper respiratory infections
Important warnings
- Increases risk of serious meningococcal and other encapsulated-bacteria infections.
- Vaccination against meningococcal disease is required before treatment when feasible.
- Seek urgent care for fever, severe headache, rash, confusion, or rapid breathing.
- May cause infusion reactions and serious allergic reactions.
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential risk.
Breastfeeding
It is unknown whether crovalimab passes into breast milk; effects on infants are unknown.
Interactions
- Can interfere with laboratory tests using certain complement reagents, causing inaccurate results.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.